China Pharma Holdings Revenue 2012-2026 | CPHI
China Pharma Holdings revenue from 2012 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
|
China Pharma Holdings Annual Revenue (Millions of US $) |
|
|---|---|
| 2025 | $4 |
| 2024 | $5 |
| 2023 | $7 |
| 2022 | $8 |
| 2021 | $10 |
| 2020 | $11 |
| 2019 | $11 |
| 2018 | $12 |
| 2017 | $13 |
| 2016 | $16 |
| 2015 | $20 |
| 2014 | $22 |
| 2013 | $33 |
| 2012 | $55 |
| 2011 | $81 |
|
China Pharma Holdings Quarterly Revenue (Millions of US $) |
|
|---|---|
| 2026-03-31 | $1 |
| 2025-12-31 | $1 |
| 2025-09-30 | $1 |
| 2025-06-30 | $1 |
| 2025-03-31 | $1 |
| 2024-12-31 | $1 |
| 2024-09-30 | $1 |
| 2024-06-30 | $1 |
| 2024-03-31 | $1 |
| 2023-12-31 | $2 |
| 2023-09-30 | $2 |
| 2023-06-30 | $1 |
| 2023-03-31 | $2 |
| 2022-12-31 | $3 |
| 2022-09-30 | $2 |
| 2022-06-30 | $2 |
| 2022-03-31 | $2 |
| 2021-12-31 | $3 |
| 2021-09-30 | $2 |
| 2021-06-30 | $2 |
| 2021-03-31 | $2 |
| 2020-12-31 | $3 |
| 2020-09-30 | $2 |
| 2020-06-30 | $4 |
| 2020-03-31 | $2 |
| 2019-12-31 | $3 |
| 2019-09-30 | $2 |
| 2019-06-30 | $3 |
| 2019-03-31 | $3 |
| 2018-12-31 | $3 |
| 2018-09-30 | $2 |
| 2018-06-30 | $3 |
| 2018-03-31 | $4 |
| 2017-12-31 | $4 |
| 2017-09-30 | $3 |
| 2017-06-30 | $3 |
| 2017-03-31 | $3 |
| 2016-12-31 | $5 |
| 2016-09-30 | $3 |
| 2016-06-30 | $4 |
| 2016-03-31 | $4 |
| 2015-12-31 | $5 |
| 2015-09-30 | $4 |
| 2015-06-30 | $6 |
| 2015-03-31 | $6 |
| 2014-12-31 | $3 |
| 2014-09-30 | $6 |
| 2014-06-30 | $6 |
| 2014-03-31 | $7 |
| 2013-12-31 | $8 |
| 2013-09-30 | $8 |
| 2013-06-30 | $8 |
| 2013-03-31 | $8 |
| 2012-12-31 | $12 |
| 2012-09-30 | $12 |
| 2012-06-30 | $15 |
| 2012-03-31 | $16 |
| 2011-12-31 | $22 |
| 2011-09-30 | $21 |
| 2011-06-30 | $20 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.026B | $0.004B |
| CHINA PHARMA HOLDINGS, Inc. develops, manufactures, and markets generic and brand bio-pharmaceutical products in China that treat a wide range of conditions, including infections, hepatitis, cardiovascular and CNS diseases, and other prevailing diseases. Helpson Bio-pharmaceutical Co., Ltd. (Helpson), a specialty pharmaceutical company headquartered in Haikou City, Hainan province in China, is a wholly owned subsidiary of China Pharma Holdings. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |